Qing Re Liang Xue Decoction Alleviates Hypercoagulability in Kawasaki Disease

Area of Science:

• Pediatrics
• Immunology
• Rheumatology

Background:

• Kawasaki disease (KD) is a critical autoimmune vasculitis affecting multiple systems in children.
• Intravenous immunoglobulin (IVIG) is the standard first-line therapy for KD.
• The role of Traditional Chinese Medicine (TCM) in managing KD remains under investigation.

Purpose of the Study:

• To evaluate the clinical efficacy of TCM, specifically Qing Re Liang Xue decoction, in treating acute KD.
• To assess the impact of this integrative medicine approach on serum levels of interleukin-33 (IL-33) and tumor necrosis factor-alpha (TNF-α).

Main Methods:

• A comparative study involving 31 KD patients treated with Qing Re Liang Xue decoction plus Western medicine versus 28 KD patients receiving Western medicine alone.
• Inclusion of a febrile group (30 patients) and a healthy control group (28 children) for comparison.
• Measurement of serum IL-33 and TNF-α levels using multiplex Luminex assay.

Main Results:

• The integrative medicine group showed a significantly lower platelet count compared to the Western medicine group.
• Patients receiving integrative treatment experienced shorter fever duration and reduced levels of IL-33 and TNF-α.
• No significant differences were observed between the two KD treatment groups post-therapy regarding certain parameters.

Conclusions:

• Qing Re Liang Xue decoction appears to mitigate the hypercoagulable state associated with Kawasaki disease.
• Further research is warranted to explore the potential cardioprotective effects of this TCM intervention in KD patients.